Last $4.00 USD
Change Today -0.03 / -0.74%
Volume 36.3K
PSDV On Other Exchanges
As of 5:10 PM 12/24/14 All times are local (Market data is delayed by at least 15 minutes).

psivida corp (PSDV) Snapshot

Previous Close
Day High
Day Low
52 Week High
01/17/14 - $5.45
52 Week Low
04/14/14 - $3.26
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for PSIVIDA CORP (PSDV)

psivida corp (PSDV) Related Businessweek News

No Related Businessweek News Found

psivida corp (PSDV) Details

pSivida Corp. develops products to deliver drugs and biologics in the United States and the United Kingdom. The company develops its products based on its Durasert and Tethadur drug delivery technologies focusing on the treatment of chronic diseases of the back of the eye. It offers ILUVIEN, an injectable, sustained-release micro-insert for use in treating vision impairment associated with diabetic macular edema; and Retisert for the treatment of posterior uveitis. The company also provides Medidur, an injectable, sustained-release micro-insert designed to treat non-infectious uveitis affecting the posterior segment of the eye, which is in Phase III clinical trial.It has strategic collaborations with Alimera Sciences, Inc.; Pfizer, Inc.; Bausch & Lomb Incorporated; Enigma Therapeutics Limited; and Intrinsiq Materials Cayman Limited. The company was founded in 1987 and is headquartered in Watertown, Massachusetts.

24 Employees
Last Reported Date: 09/11/14
Founded in 1987

psivida corp (PSDV) Top Compensated Officers

Chief Executive Officer, President and Execut...
Total Annual Compensation: $708.6K
Principal Financial & Accounting Officer and ...
Total Annual Compensation: $316.0K
Vice President of Corporate Affairs, General ...
Total Annual Compensation: $433.5K
Compensation as of Fiscal Year 2014.

psivida corp (PSDV) Key Developments

pSivida Receives Marketing Authorization in Belgium for ILUVIEN

pSivida Corp. announced that the Belgian Federal Agency for Medicines and Health Products (FAMHP) has granted marketing authorization to ILUVIEN for the treatment of vision impairment associated with chronic diabetic macular edema (DME) considered insufficiently responsive to available therapies.

pSivida Corp. Presents at LD Micro Conference, Dec-03-2014 12:00 PM

pSivida Corp. Presents at LD Micro Conference, Dec-03-2014 12:00 PM. Venue: Luxe Sunset Boulevard Hotel, 11461 Sunset Boulevard, Los Angeles, California, United States. Speakers: Paul Ashton, Chief Executive Officer, President and Executive Director.

pSivida Corp. Reports Unaudited Consolidated Earnings Results for the First Quarter Ended September 30, 2014

pSivida Corp. reported unaudited consolidated earnings results for the first quarter ended September 30, 2014. For the quarter, the company’s total revenues were $25,307,000 compared to $597,000 for the prior year quarter. The increase was due to recognition of the $25.0 million milestone earned upon FDA approval of ILUVIEN. Net income was $20.6 million or $0.67 per diluted share compared to net loss of $3.7 million or $0.14 per share for the prior year quarter. Income from operations was $20,789,000 compared to loss from operations of $3,718,000 a year ago. Income before income taxes was $20,792,000 compared to loss before income taxes of $3,717,000 a year ago. Cash used in operating activities was $4 million, an increase of $200,000 over the prior year quarter.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
PSDV:US $4.00 USD -0.03

PSDV Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Allergan Inc/United States $210.12 USD +0.95
Regeneron Pharmaceuticals Inc $400.12 USD +6.07
View Industry Companies

Industry Analysis


Industry Average

Valuation PSDV Industry Range
Price/Earnings 10.5x
Price/Sales 4.2x
Price/Book 3.3x
Price/Cash Flow 10.8x
TEV/Sales 3.7x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact PSIVIDA CORP, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at